Companies › Ono Pharmaceutical
18 active drug programs in 41 registered trials: 22 Phase 1, 13 Phase 2, 6 Phase 3; Oncology, Neurology, Immunology, Genitourinary; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Cenobamate GABA-A receptor; anion channel positive allosteric modulator; Sodium channel alpha subunit inhibitor | GABRA1, GABRB2, GABRG2, GABRB3, GABRA4 | Phase 3 | Partial Epilepsy; Epilepsies, Partial | Jan 2027 |
| ONO-2017 Sodium channel modulator; GABA-A receptor positive allosteric modulator | Ion channels, GABRA1 | Phase 3 | Epilepsy, Generalized | Jan 2027 |
| Tirabrutinib Tyrosine-protein kinase BTK inhibitor | BTK | Phase 3 | Pemphigus; Relapsed/Refractory Primary Central Nervous System Lymphoma; Refractory Primary Central Nervous System Lymphoma; Primary Central Nervous System Lymphoma | Mar 2027 |
| Nivolumab (ONO-4538) Programmed cell death protein 1 inhibitor | PDCD1 | Phase 3 | Gastric Cancer; Pan-tumor; Colorectal Cancer; Rhabdoid Tumor … | May 2027 |
| Sapablursen (ONO-0530) Transmembrane protease serine 6 mRNA antisense inhibitor | TMPRSS6 | Phase 3 | Polycythemia Vera | Sep 2028 |
| ONO-2020 Epigenetic regulator | – | Phase 2 | Alzheimer Disease; Agitation Associated With Alzheimer's Disease Dementia | Dec 2026 |
| ONO-4578 unclear mechanism | – | Phase 2 | Gastric Cancer; Colorectal Cancer; Non-small Cell Lung Cancer; Advanced or Metastatic Solid Tumors | Jul 2027 |
| ONO-2808 | – | Phase 2 | Multiple System Atrophy (MSA) | Oct 2027 |
| ONO-7703 | – | Phase 2 | Pan-tumor | Dec 2027 |
| Magrolimab (ONO-7913) Leukocyte surface antigen CD47 inhibitor | CD47 | Phase 1 | Metastatic Pancreatic Cancer; Unresectable Colorectal Cancer | Jun 2027 |
| ONO-4685 | – | Phase 1 | Relapsed or Refractory T Cell Lymphoma; Relapsed or Refractory T Cell Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Aug 2027 |
| ONO-7475 TBD - mechanism unclear for investigational code-named drug | – | Phase 1 | Metastatic Pancreatic Cancer | Sep 2027 |
| ONO-3310 | – | Phase 1 | Type2 Diabetes Mellitus | Nov 2027 |
| ONO-6414 | – | Phase 1 | Ulcerative Colitis (UC) | Dec 2027 |
| Ripretinib (DCC-2618) Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor alpha inhibitor | KIT, PDGFRA | Phase 1 | Gastrointestinal Stromal Tumors | Feb 2028 |
| ONO-4538HSC PD-1 inhibitor | PDCD1 | Phase 1 | Advanced or Metastatic Solid Tumors; Pediatric Malignant Solid Tumor and Epithelioid Sarcoma | Feb 2028 |
| ONO-7429 | – | Phase 1 | Solid Tumors | Jul 2028 |
| ONO-7428 | – | Phase 1 | Solid Tumor | Jul 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06542731 | Nivolumab (ONO-4538) | Phase 1 | Non-small Cell Lung Cancer | Oncology | Oct 2025 |
| NCT06542731 | ONO-4578 | Phase 1 | Non-small Cell Lung Cancer | Oncology | Oct 2025 |
| NCT06881836 | ONO-2020 | Phase 2 | Alzheimer Disease | Neurology | Jul 2026 |
| NCT06803823 | ONO-2020 | Phase 2 | Agitation Associated With Alzheimer's Disease Dementia | Neurology | Dec 2026 |
| NCT06590896 | Cenobamate | Phase 2 | Epilepsies, Partial | Neurology | Jan 2027 |
| NCT06579573 | ONO-2017 | Phase 3 | Epilepsy, Generalized | Neurology | Jan 2027 |
| NCT04947319 | Tirabrutinib | Phase 2 | Refractory Primary Central Nervous System Lymphoma | Oncology | Mar 2027 |
| NCT05144854 | Nivolumab (ONO-4538) | Phase 3 | Gastric Cancer | Oncology | May 2027 |
| NCT06532344 | Nivolumab (ONO-4538) | Phase 1 | Metastatic Pancreatic Cancer | Oncology | Jun 2027 |
| NCT06532344 | Magrolimab (ONO-7913) | Phase 1 | Metastatic Pancreatic Cancer | Oncology | Jun 2027 |
| NCT06256328 | ONO-4578 | Phase 2 | Gastric Cancer | Oncology | Jul 2027 |
| NCT05079282 | ONO-4685 | Phase 1 | Relapsed or Refractory T Cell Lymphoma | Oncology | Aug 2027 |
| NCT06532331 | ONO-7475 | Phase 1 | Metastatic Pancreatic Cancer | Oncology | Sep 2027 |
| NCT06532331 | Nivolumab (ONO-4538) | Phase 1 | Metastatic Pancreatic Cancer | Oncology | Sep 2027 |
| NCT06696716 | Tirabrutinib | Phase 3 | Pemphigus | Immunology | Sep 2027 |
| NCT06547385 | Nivolumab (ONO-4538) | Phase 1 | Colorectal Cancer | Oncology | Oct 2027 |
| NCT06547385 | ONO-4578 | Phase 1 | Colorectal Cancer | Oncology | Oct 2027 |
| NCT05923866 | ONO-2808 | Phase 2 | Multiple System Atrophy (MSA) | Neurology | Oct 2027 |
| NCT07619157 | ONO-3310 | Phase 1 | Type2 Diabetes Mellitus | Genitourinary | Nov 2027 |
| NCT07104032 | Tirabrutinib | Phase 3 | Relapsed/Refractory Primary Central Nervous System Lymphoma | Oncology | Dec 2027 |
| NCT04566380 | Nivolumab (ONO-4538) | Phase 2 | Pan-tumor | Oncology | Dec 2027 |
| NCT06540261 | Nivolumab (ONO-4538) | Phase 1 | Unresectable Colorectal Cancer | Oncology | Dec 2027 |
| NCT07749768 | ONO-6414 | Phase 1 | Ulcerative Colitis (UC) | Immunology | Dec 2027 |
| NCT04566380 | ONO-7703 | Phase 2 | Pan-tumor | Oncology | Dec 2027 |
| NCT06540261 | Magrolimab (ONO-7913) | Phase 1 | Unresectable Colorectal Cancer | Oncology | Dec 2027 |
| NCT06948448 | Nivolumab (ONO-4538) | Phase 2 | Colorectal Cancer | Oncology | Feb 2028 |
| NCT06948448 | ONO-4578 | Phase 2 | Colorectal Cancer | Oncology | Feb 2028 |
| NCT07618377 | Ripretinib (DCC-2618) | Phase 1 | Gastrointestinal Stromal Tumors | Oncology | Feb 2028 |
| NCT06548217 | ONO-4538HSC | Phase 1 | Advanced or Metastatic Solid Tumors | Oncology | Feb 2028 |
| NCT03155061 | Nivolumab (ONO-4538) | Phase 1 | Advanced or Metastatic Solid Tumors | Oncology | Mar 2028 |
| NCT03155061 | ONO-4578 | Phase 1 | Advanced or Metastatic Solid Tumors | Oncology | Mar 2028 |
| NCT07594158 | Cenobamate | Phase 3 | Partial Epilepsy | Neurology | Mar 2028 |
| NCT06541665 | Tirabrutinib | Phase 1 | Primary Central Nervous System Lymphoma | Oncology | Apr 2028 |
| NCT07787208 | ONO-7429 | Phase 1 | Solid Tumors | Oncology | Jul 2028 |
| NCT07429266 | Sapablursen (ONO-0530) | Phase 3 | Polycythemia Vera | Oncology | Sep 2028 |
| NCT06622941 | Nivolumab (ONO-4538) | Phase 2 | Rhabdoid Tumor | Oncology | Jan 2029 |
| NCT06547528 | ONO-4685 | Phase 1 | Relapsed or Refractory T Cell Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Oncology | Jan 2029 |
| NCT06816108 | ONO-7428 | Phase 1 | Solid Tumor | Oncology | Jul 2029 |
| NCT06936943 | Nivolumab (ONO-4538) | Phase 2 | Richter's Transformation | Oncology | Jul 2029 |
| NCT07734116 | ONO-4538HSC | Phase 1 | Pediatric Malignant Solid Tumor and Epithelioid Sarcoma | Oncology | Nov 2029 |
| NCT06940791 | Tirabrutinib | Phase 2 | Primary Central Nervous System Lymphoma | Oncology | Feb 2030 |
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Haisco Pharmaceutical Group Akeso Merck KGaA Sichuan Baili Pharmaceutical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.